Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
publications [2023/12/26 17:29] ramirez [2023] |
publications [2024/02/13 16:00] ramirez [2024] |
||
---|---|---|---|
Line 2: | Line 2: | ||
===== 2024 ===== | ===== 2024 ===== | ||
+ | Mendes Pedro D, Paulo SE, Santos CM, Fonseca AB, [[people:jmelocristino|Melo-Cristino J]], Pereira AA, Caneiras C. 2024. <fc #0000FF>Extensively drug-resistant //Pseudomonas aeruginosa//: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study</fc>. Frontiers in Microbiology 15. //In press// | ||
- | [[people:anacosta|Silva-Costa C]], [[people:jmelocristino|Melo-Cristino J]], [[people:ramirez|Ramirez M.]] 2024. <fc #0000FF>//Streptococcus pneumoniae//</fc>, p. 1479–1490. In Tang, Y-W, Hindiyeh, MY, Liu, D, Sails, A, Spearman, P, Zhang, J-R (eds.), Molecular Medical Microbiology (Third Edition). Academic Press. [[https://doi.org/10.1016/B978-0-12-818619-0.00095-2|doi:10.1016/B978-0-12-818619-0.00095-2]] | + | Bajanca-Lavado MP, Pinto M, Carvalho MD, Jantarada Domingos G, [[people:jmelocristino|Melo-Cristino J]]. 2024. <fc #0000FF>Rare serotype c //Haemophilus influenzae// invasive isolate: characterization of the first case in Portugal</fc>. Eur J Clin Microbiol Infect Dis //In press// [[https://www.ncbi.nlm.nih.gov/pubmed/38332396/|(PMID: 38332396)]] |
+ | [[people:anacosta|Silva-Costa C]], [[people:jmelocristino|Melo-Cristino J]], [[people:ramirez|Ramirez M.]] 2024. <fc #0000FF>//Streptococcus pneumoniae//</fc>, p. 1479–1490. In Tang, Y-W, Hindiyeh, MY, Liu, D, Sails, A, Spearman, P, Zhang, J-R (eds.), Molecular Medical Microbiology (Third Edition). Academic Press. [[https://doi.org/10.1016/B978-0-12-818619-0.00095-2|doi:10.1016/B978-0-12-818619-0.00095-2]][[https://www.sciencedirect.com/science/article/abs/pii/B9780128186190000952 | ||
+ | |Publisher site]] | ||
===== 2023 ===== | ===== 2023 ===== | ||
- | [[people:anacosta|Silva-Costa C]], Gomes-Silva J, Santos A, [[people:ramirez|Ramirez M]], [[people:jmelocristino|Melo-Cristino J]], The Portuguese Group for the Study of Streptococcal Infections. 2023. <fc #0000FF>Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children</fc>. Frontiers in Public Health 11. [[ https://doi.org/10.3389/fpubh.2023.1279656|(doi: 10.3389/fpubh.2023.1279656)]] | + | [[people:anacosta|Silva-Costa C]], Gomes-Silva J, Santos A, [[people:ramirez|Ramirez M]], [[people:jmelocristino|Melo-Cristino J]], The Portuguese Group for the Study of Streptococcal Infections. 2023. <fc #0000FF>Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children</fc>. Frontiers in Public Health 11:1279656 [[https://www.ncbi.nlm.nih.gov/pubmed/38186693/|(PMID: 38186693)]] |
Mendes G, Santos ML, Ramalho JF, Bruschy-Fonseca A, Lito L, Mendes-Pedro D, Duarte A, [[people:jmelocristino|Melo-Cristino J]], Caneiras C. 2023. <fc #0000FF>Genomic characterisation of a novel KPC-98-producing clinical //Klebsiella pneumoniae// strain conferring resistance to ceftazidime/avibactam</fc>. Int J Antimicrob Agents 62:107013. [[https://www.ncbi.nlm.nih.gov/pubmed/37875180/|(PMID: 37875180)]] | Mendes G, Santos ML, Ramalho JF, Bruschy-Fonseca A, Lito L, Mendes-Pedro D, Duarte A, [[people:jmelocristino|Melo-Cristino J]], Caneiras C. 2023. <fc #0000FF>Genomic characterisation of a novel KPC-98-producing clinical //Klebsiella pneumoniae// strain conferring resistance to ceftazidime/avibactam</fc>. Int J Antimicrob Agents 62:107013. [[https://www.ncbi.nlm.nih.gov/pubmed/37875180/|(PMID: 37875180)]] |